No data to show
XNAS
PLRX
Market cap83mUSD
Jul 09, Last price
1.36USD
1D
14.29%
1Q
8.37%
IPO
-94.18%
Name
Pliant Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.23%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-210m
L+30.35%
CFO
-156m
L+33.64%
Earnings
Aug 05, 2025
Profile
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 1,580 -83.69% | 9,685 27.91% | ||||||
Cost of revenue | 228,365 | 185,725 | 140,566 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (228,365) | (184,145) | (130,881) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (1,823) | |||||||
Tax Rate | ||||||||
NOPAT | (228,365) | (184,145) | (129,058) | |||||
Net income | (210,304) 30.35% | (161,336) 32.79% | (121,498) 578.49% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 3,207 | 275,252 | 217,561 | |||||
BB yield | -0.40% | -25.88% | -26.79% | |||||
| Debt | ||||||||
Debt current | 1,084 | 2,636 | 2,457 | |||||
Long-term debt | 60,192 | 11,372 | 19,244 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 29,439 | |||||||
Net debt | (294,448) | (480,237) | (309,486) | |||||
| Cash flow | ||||||||
Cash from operating activities | (155,503) | (116,361) | (94,631) | |||||
CAPEX | (3,848) | (921) | (1,760) | |||||
Cash from investing activities | 140,340 | (127,012) | (150,204) | |||||
Cash from financing activities | 23,117 | 274,405 | 226,854 | |||||
FCF | (256,355) | (179,015) | (128,030) | |||||
| Balance | ||||||||
Cash | 355,724 | 494,245 | 331,187 | |||||
Long term investments | ||||||||
Excess cash | 355,724 | 494,166 | 330,703 | |||||
Stockholders' equity | (710,046) | (499,397) | (340,365) | |||||
Invested Capital | 1,074,861 | 985,663 | 669,522 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 60,539 | 58,719 | 42,016 | |||||
Price | 13.17 -27.28% | 18.11 -6.31% | 19.33 43.19% | |||||
Market cap | 797,294 -25.02% | 1,063,403 30.93% | 812,168 67.83% | |||||
EV | 502,846 | 583,166 | 502,682 | |||||
EBITDA | (226,240) | (182,304) | (129,058) | |||||
EV/EBITDA | ||||||||
Interest | 21,085 | 1,267 | 791 | |||||
Interest/NOPBT | ||||||||